Ventas (NYSE:VTR) Price Target Raised to $99.00 at Royal Bank Of Canada

Ventas (NYSE:VTR) had its price target increased by Royal Bank Of Canada from $98.00 to $99.00 in a report published on Friday,Benzinga reports. The firm currently has an outperform rating on the real estate investment trust’s stock.

Other analysts have also issued reports about the company. JPMorgan Chase & Co. lifted their price target on Ventas from $93.00 to $94.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Evercore reaffirmed an “outperform” rating and issued a $95.00 price objective on shares of Ventas in a research note on Wednesday, April 29th. The Goldman Sachs Group reiterated a “buy” rating and issued a $110.00 price objective on shares of Ventas in a report on Tuesday, May 19th. Scotiabank cut their target price on shares of Ventas from $95.00 to $88.00 and set a “sector perform” rating on the stock in a research report on Thursday, June 18th. Finally, UBS Group boosted their target price on shares of Ventas from $85.00 to $93.00 and gave the stock a “neutral” rating in a report on Monday, May 4th. Fifteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $98.00.

Ventas Trading Up 1.3%

NYSE VTR opened at $91.48 on Friday. The company has a market cap of $46.92 billion, a price-to-earnings ratio of 169.40, a price-to-earnings-growth ratio of 2.08 and a beta of 0.69. Ventas has a twelve month low of $66.38 and a twelve month high of $101.60. The company has a quick ratio of 0.44, a current ratio of 0.44 and a debt-to-equity ratio of 0.86. The business’s fifty day moving average is $90.45 and its 200 day moving average is $86.54.

Insider Activity at Ventas

In related news, Director Michael J. Embler purchased 2,500 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $78.81 per share, with a total value of $197,025.00. Following the completion of the purchase, the director owned 19,202 shares in the company, valued at approximately $1,513,309.62. This represents a 14.97% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.53% of the company’s stock.

Hedge Funds Weigh In On Ventas

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Ventas during the 2nd quarter valued at approximately $4,953,439,000. Capital World Investors acquired a new position in shares of Ventas in the 4th quarter worth approximately $594,116,000. Norges Bank acquired a new position in shares of Ventas in the 4th quarter worth approximately $474,571,000. Legal & General Group Plc bought a new stake in shares of Ventas in the 2nd quarter valued at $501,850,000. Finally, Deutsche Bank AG bought a new stake in shares of Ventas in the 2nd quarter valued at $451,822,000. 94.18% of the stock is owned by institutional investors and hedge funds.

Ventas Company Profile

Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas’ business model combines property ownership with active asset management and capital markets activity.